DOCSLIB.ORG

Pharmacology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacology O Magazine&G Vol 16 No 2 Winter 2014 Pharmacology The Royal Australian and New Zealand College of Obstetricians and Gynaecologists Contents Contents RANZCOG Regional Committees New Zealand The College Dr Ian Page Chair Pharmacology Jane Cumming Executive Officer 5 From the President Level 6 Featherson Tower 13 Editorial 23 Waring Taylor Street/ PO Box 10611 Michael Permezel Wellington 6011, NEW ZEALAND OMagazine& G John Schibeci (t) +64 4 472 4608 (f) +64 4 472 4609 (e) [email protected] 11 From the College O&G Magazine Advisory Group 14 Combined oral contraceptives Dr Gillian Gibson Fellows Rep, New Zealand Stephen Robson Australian Capital Territory Mary Stewart, Betty Chaar and Deborah Bateson TBA Chair A/Prof Stephen Robson Fellows Rep, ACT Dr John Schibeci Diplomates Rep, NSW 62 Intrapartum care in Kiribati 18 The enduring duo New South Wales Dr Brett Daniels Young Fellows Rep, TAS Prof Gabrielle Casper Chair Carmel Walker Dr Alexa Bendall Trainees Rep, QLD Elizabeth Todd and Brett Daniels Lee Dawson Executive Officer Suite 4, Level 5, 69 Christie Street Magazine Editors 64 The Skyline’s the limit ST LEONARDS, NSW 2065 O&G 20 Pharmacology of ART (t) +61 2 9436 1688 (f) +61 2 9436 4166 Penelope Griffiths (e) [email protected] Simon McDowell, Ben Kroon, Anush Yazdani Julia Serafin 65 Award-winning journalism Queensland Lisa Westhaven Dr Lee Minuzzo Chair 22 Uterotonics and tocolytics Lee-Anne Harris Executive Officer Designer and Production Editor 68 Research at the forefront Unit 22, Level 3, 17 Bowen Bridge Road Lisa Westhaven Lucy Bates HERSTON, QLD 4006 (t) +61 7 3252 3073 (f) +61 7 3257 2370 69 News from the Museum Editorial Communications (e) [email protected] 25 Hyperemesis gravidarum Magazine Advisory Group, Gráinne Murphy South Australia/Northern Territory O&G Dr Roy Watson Chair RANZCOG Heena Lakhdhir and Jenny McDougall Tania Back Executive Officer 254–260 Albert Street 69 RANZCOG Women’s Health Award 2013 1–54 Palmer Place/PO Box 767 EAST MELBOURNE, VIC 3002 Australia North ADELAIDE, SA 5006 27 Pre-eclampsia Julia Serafin (t) +61 8 8267 4377 (f) +61 8 8267 5700 (t) +61 3 9417 1699 Dean Fourie and Lucille Wilkinson (e) [email protected] (f) +61 3 9419 0672 Tasmania (e) [email protected] 70 Staff news Dr Emily Hooper Chair 30 Magnesium sulphate 70 Notice of deceased Fellows Mathew Davies Executive Officer Advertising Sales College House Stephen Robson Bill Minnis Director 72 Obituaries 254–260 Albert Street EAST MELBOURNE, VIC 3002 Minnis Journals (t) +61 3 9663 5606 (f) + 61 3 9662 3908 (t) +61 3 9836 2808 32 Prostaglandins (e) [email protected] (f) +61 3 9830 4500 John Schibeci Victoria (e) [email protected] A Pocket Guide to Dr Alison Fung Chair Mathew Davies Executive Officer 40 Anaesthetics College House Printer Medicines Your Patients Take 254–260 Albert Street Highway Press Martin Steynor and Kerry Holmes EAST MELBOURNE, VIC 3002 2 Respiratory medications (t) +61 3 9887 1388 (t) +61 3 9663 5606 (f) + 61 3 9662 3908 (e) [email protected] (f) +61 3 9800 2270 Lucille Wilkinson 42 Endometriosis Western Australia Graham Tronc Dr Tamara Walters Chair 3 Anticoagulants Janet Davidson Executive Officer O&G Magazine authorised by Level 1, 44 Kings Park Road Mr James McAdam © 2014 The Royal 44 Recurrent miscarriage Alexa Bendall WEST PERTH, WA 6005/PO Box 6258 Australian and New Zealand College EAST PERTH, WA 6892 (t) +61 8 9322 1051 (f) +61 8 6263 4432 of Obstetricians and Gynaecologists Stephen Robson 4 A shrink’s shrunken guide to psychopharmacology (e) [email protected] (RANZCOG). All rights reserved. No part The Royal Australian of this publication may be reproduced or 47 The safety of drugs in pregnancy and breastfeeding Yvette A Kelly and New Zealand College of Obstetricians copied in any form or by any means without Debra Kennedy and Gynaecologists the written permission of the publisher. The 6 Drugs for inflammatory bowel disease during pregnancy College House submission of articles, news items and letters is 254–260 Albert Street 50 Perinatal mental health Bruce McGarity EAST MELBOURNE, VIC 3002 encouraged. (t) +61 3 9417 1699 (f) +61 3 9417 0672 Vijay Roach, Marie-Paule Austin and Debra Kennedy (e) [email protected] For further information about contributing to 7 Rheumatology medications (w) www.ranzcog.edu.au Magazine visit: www.ranzcog.edu.au/ O&G 53 Menopause pharmacology San Wong publications/oandg-magazine.html Michele Kwik and Rod Baber The statements and opinions expressed in 9 Hypertension articles, letters and advertisements in President O&G Emma Skowronski Magazine are those of the authors and, unless Women’s health Prof Michael Permezel specifically stated, are not necessarily the 56 Saved by fetal surveillance Vice Presidents Board Members views of RANZCOG. 10 Common dermatological drugs in pregnancy A/Prof Stephen Robson Dr Vijay Roach Will Twycross Dr Sarah Tout Dr Gino Pecoraro Although all advertising material is expected Sonya Havill to conform to ethical and legal standards, Treasurer Chief Executive Officer 60 Journal Club Dr Martin Ritossa Mr James McAdam acceptance does not imply endorsement by 12 Thyroid medication Brett Daniels the College. AK Greenaway and TM Greenaway ISSN 1442-5319 Cover: Shutterstock 172490864 © Dima 61 Q&a: the small-for-dates fetus 14 Anti-epileptic medications Sobko. Pocket Guide cover: Shutterstock Chris Wilkinson 131830784 © Sinisa Botas. Penny Gordon 2 O&G Magazine Vol 16 No 2 Winter 2014 3 The College ® ™ Introducing Mirena EvoInserter From the President Mirena® already pre loaded in the correct horizontal position I write to you having recently attended Education and training an outstanding Indigenous Women’s Examinations Health Meeting in Adelaide. Much As this has to be written some weeks before publication, my registrars more needs to be done at all levels, are currently preparing for their May Structured Oral Examinations but many Fellows, Diplomates (SOE). The College is rightly proud that it has been a leader in Loading by pushing the slider and Trainees are making great examination processes such as the rigour employed in the reviewing contributions to Indigenous women’s and workshopping of cases and in our standard-setting procedures. forwards to its furthest position Double-sided health, both in Australia and New Further positive developments continue and the College will always centimetre scale Zealand. Indigenous women’s health strive for fair and transparent assessment processes that ensure new is embedded in the FRANZCOG Fellows achieve the standard necessary for best-practice outcomes in Curriculum and it is pleasing to note women’s health. Threads are inside the plans to further increase online Prof Michael Permezel resources and increased incorporation Examining for the College is one of the most rewarding ways for a the inserter handle into College assessments. Fellow or Diplomate to make a contribution; having a productive President exchange with senior colleagues in developing examination questions The highlight of the meeting was – while accruing significant CPD points. In encouraging colleagues to the launch of the College’s Reconciliation Action Plan (RAP). The become examiners, the response is often: I am a clinician, examining Ergonomic shape of development of a RAP was initiated by the Indigenous Women’s is for academics. Nothing could be further from the truth. The essence slider and handle Health Committee in 2012. Aboriginal Fellow Dr Marilyn Clarke of College examinations is assessment by contemporary peers. It chaired a Working Party that, in consultation with Reconciliation is precisely those who describe themselves as a clinician not an Australia, developed a plan that sets measurable and achievable academic who are most needed as examiners. goals, timelines and responsibilities to provide the necessary framework for that change to occur. Marilyn, Dr Jacquie Boyle (Chair What is the meaning of MRANZCOG? of the Indigenous Women’s Health Committee) and the Working Awarding MRANZCOG dates back to a time where many of the Party are to be congratulated on this important development towards specialist Colleges had Membership awarded during training, as a ultimately ‘Closing the Gap’ in Aboriginal and Torres Strait Islander staging point on the way to Fellowship. RANZCOG remains one of women’s health. The RAP is available on the College website at: www. the very few Colleges to retain a post-nominal (MRANZCOG) that ranzcog.edu.au/womens-health/reconciliation-action-plan.html . does not meaningfully translate to readiness for specialist practice. Mirena® Evoinserter™ introduces a “one-stop” loading system to prepare the device prior to patient insertion. ® 1 Level 7, 14 Martin Place Sydney NSW 2000 Importantly, Mirena itself remains unchanged. T +61 2 8248 2900 F +61 2 9475 4345 E [email protected] W www.globalmedics.com Please contact your Bayer Women’s healthcare representative or email Obstetrics & Gynaecology Registrars Urgently Needed [email protected] for further information. Due to a current shortage Global Medics are looking for Obstetrics & Gynaecology Registrars for short and long term locum positions to assist hospitals in Australia for the second half of 2014 MIRENA® Minimum Product Information Mirena®, levonorgestrel 52 mg, intrauterine drug delivery system. Indications: Contraception, idiopathic menorrhagia and prevention of endometrial hyperplasia during Global Medics has been assisting hospitals in Rural and Metro oestrogen replacement therapy. Contraindications: Known/suspected pregnancy; current or recurrent pelvic infl ammatory disease; lower genital tract infection; postpartum areas across Australia, New Zealand, UK, Ireland and Canada endometritis; infected abortion during the past three months; cervicitis; cervical dysplasia; uterine or cervical malignancy; progestogen-dependent tumours; undiagnosed for over 12 years. abnormal uterine bleeding; congenital or acquired uterine anomaly including fi broids if they distort the uterine cavity; conditions associated with increased infection susceptibility; Our personalised service with a dedicated specialist acute liver disease/ tumour; hypersensitivity to the constituents.
Load more

Recommended publications
  • Optum Essential Health Benefits Enhanced Formulary PDL January
    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
    [Show full text]
  • Classification and Pharmacology of Progestins
    Maturitas 46S1 (2003) S7–S16 Classification and pharmacology of progestins Adolf E. Schindler a,∗, Carlo Campagnoli b, René Druckmann c, Johannes Huber d, Jorge R. Pasqualini e, Karl W. Schweppe f, Jos H. H. Thijssen g a Institut für Medizinische Forschung und Fortbildung, Universitätsklinikum, Hufelandstr. 55, Essen 45147, Germany b Ospedale Ginecologico St. Anna, Corso Spezia 60, 10126 Torino, Italy c Ameno-Menopause-Center, 12, Rue de France, 06000 Nice, France d Abt. für Gynäkologische Endokrinologie, AKH Wien, Währingergürtel 18-20, 1090 Wien, Austria e Institute de Puériculture26, Boulevard Brune, 75014 Paris, France f Abt. für Gynäkologie und Geburtshilfe, Ammerland Klinik, Langestr.38, 26622 Westerstede, Germany g Department of Endocrinology, Universitair Medisch Centrum Utrecht, P.O. Box 85090, 3508 AB Utrecht, The Netherlands Abstract Besides the natural progestin, progesterone, there are different classes of progestins, such as retroprogesterone (i.e. dydroges- terone), progesterone derivatives (i.e. medrogestone) 17␣-hydroxyprogesterone derivatives (i.e. chlormadinone acetate, cypro- terone acetate, medroxyprogesterone acetate, megestrol acetate), 19-norprogesterone derivatives (i.e. nomegestrol, promege- stone, trimegestone, nesterone), 19-nortestosterone derivatives norethisterone (NET), lynestrenol, levonorgestrel, desogestrel, gestodene, norgestimate, dienogest) and spironolactone derivatives (i.e. drospirenone). Some of the synthetic progestins are prodrugs, which need to be metabolized to become active compounds. Besides
    [Show full text]
  • MIRENA Data Sheet Vx3.0, CCDS 25 1
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME MIRENA 52 mg intrauterine contraceptive device (release rate: 20 microgram/24 hours) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION MIRENA is an intrauterine system (IUS) containing 52 mg levonorgestrel. For details of release rates, see Section 5.2. For the full list of excipients, see Section 6.1. 3. PHARMACEUTICAL FORM MIRENA consists of a white or almost white drug core covered with an opaque membrane, which is mounted on the vertical stem of a T-body. The vertical stem of the levonorgestrel intrauterine system is loaded in the insertion tube at the tip of the inserter. Inserter components are an insertion tube, plunger, flange, body and slider. The white T-body has a loop at one end of the vertical stem and two horizontal arms at the other end. Brown coloured removal threads are attached to the loop. The T-body of MIRENA contains barium sulfate, which makes it visible in X-ray examination. The IUS and inserter are essentially free from visible impurities. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Contraception Treatment of idiopathic menorrhagia provided there is no underlying pathology. Prevention of endometrial hyperplasia during estrogen replacement therapy MIRENA Data Sheet Vx3.0, CCDS 25 1 4.2 Dose and method of administration MIRENA is inserted into the uterine cavity. One administration is effective for five years. The in vivo dissolution rate is approximately 20 microgram/24 hours initially and is reduced to approximately 18 microgram/24 hours after 1 year and to 10 microgram/24 hours after five years. The mean dissolution rate of levonorgestrel is about 15 microgram /24 hours over the time up to five years.
    [Show full text]
  • COMPARISON of ORAL DYDROGESTERONE and INTRAMUSCULAR PROGESTERONE in the TREATMENT of THREATENED ABORTION -..:: Biomedica
    ORIGINAL ARTICLE COMPARISON OF ORAL DYDROGESTERONE AND INTRAMUSCULAR PROGESTERONE IN THE TREATMENT OF THREATENED ABORTION QING G., HONG Y., FENG X. AND WEI R. Northwest Women’s Hospital, Xian City, Shanxi Province, China ABSTRACT Background and Objective: Threatened abortion is a common condition and presents with varied cli- nical manifestations. The aim of the study was to observe and analyze the efficacy and safety of dydro- gesterone in threatened abortion. Methods: One hundred and seventy two pregnant women with early – threatened abortion diagnosed during prenatal care in Northwest Women’s Hospital from January 2012 to December 2013, were sele- cted and randomly divided into dydrogesterone group and the progesterone group. Patients received either oral dydrogesterone or progesterone injected intramuscularly, respectively. The clinical efficacy and safety of both drugs were observed. Results: There were no significant differences in age, gravidity, parity and gestational age between the two groups (p> 0.05) and there was no significant difference in progesterone levels following treatment (p > 0.05). There were no significant differences in the success rate of fetus protection, abortion rate and treatment time between the groups (p > 0.05). Conclusion: Dydrogesterone and progesterone have significant beneficial effects in the treatment of threatened abortion, and they are easy to use and safe. Keywords: Threatened abortion; Dydrogestrone; Progesterone injection. INTRODUCTION gen and has a significant role in the prevention of early Threatened abortion is a common condition, and the contractions of the myometrium.4 It plays a key role in clinical manifestations are as follows: vaginal bleeding, inducing a protective immunomodulatory effect on the with or without lower abdominal pain, non-dilatation embryo.
    [Show full text]
  • Comparison of the Efficacy of Tibolone and Transdermal Estrogen in Treating Menopausal Symptoms in Postmenopausal Women
    https://doi.org/10.6118/jmm.19205 J Menopausal Med 2019;25:123-129 pISSN: 2288-6478, eISSN: 2288-6761 ORIGINAL ARTICLE Comparison of the Efficacy of Tibolone and Transdermal Estrogen in Treating Menopausal Symptoms in Postmenopausal Women Hyun Kyun Kim, Sung Hye Jeon, Ki-Jin Ryu, Tak Kim, Hyuntae Park Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea Objectives: This study aimed to compare the efficacy of tibolone and transdermal estrogen in treating menopausal symptoms in postmenopausal women with an intact uterus. Methods: Overall, 26 women consumed tibolone orally and 31 women received transdermal estrogen gel mixed with progestogen. The menopause rating scale (MRS) was used to assess their menopausal symptoms at their first outpatient visit and 6 months later. Results: The transdermal estrogen group showed significant improvements in more items of the MRS questionnaire. There was a favorable change in body weight in the transdermal estrogen group compared with that in the tibolone group. Depressive mood, irritability, physical and mental exhaustion, sexual and bladder problems, and joint and muscular discomfort improved only in the transdermal estrogen group, whereas heart discomfort and vaginal dryness improved only in the tibolone group. Nevertheless, the intergroup differences in each item were insignificant after adjusting for body mass index and hypertension, which differed before treatment. Conclusions: Both the therapeutic options improved menopausal symptoms within 6 months of use. However, transdermal estrogen appeared to be more effective in preventing weight gain in menopausal women than tibolone. Key Words: Hormone replacement therapy, Menopause, Tibolone, Transdermal estrogens INTRODUCTION placement therapy (HRT) increases blood coagulabil- ity by increasing clotting factor levels and decreasing Menopausal symptoms such as hot flushes, affect up antithrombin activity [3].
    [Show full text]
  • Hertfordshire Medicines Management Committee (Hmmc) Nafarelin for Endometriosis Amber Initiation – Recommended for Restricted Use
    HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) NAFARELIN FOR ENDOMETRIOSIS AMBER INITIATION – RECOMMENDED FOR RESTRICTED USE Name: What it is Indication Date Decision NICE / SMC generic decision status Guidance (trade) last revised Nafarelin A potent agonistic The hormonal December Final NICE NG73 2mg/ml analogue of management of 2020 Nasal Spray gonadotrophin endometriosis, (Synarel®) releasing hormone including pain relief and (GnRH) reduction of endometriotic lesions HMMC recommendation: Amber initiation across Hertfordshire (i.e. suitable for primary care prescribing after specialist initiation) as an option in endometriosis Background Information: Gonadorelin analogues (or gonadotrophin-releasing hormone agonists [GnRHas]) include buserelin, goserelin, leuprorelin, nafarelin and triptorelin. The current HMMC decision recommends triptorelin as Decapeptyl SR® injection as the gonadorelin analogue of choice within licensed indications (which include endometriosis) link to decision. A request was made by ENHT to use nafarelin nasal spray as an alternative to triptorelin intramuscular injection during the COVID-19 pandemic. The hospital would provide initial 1 month supply, then GPs would continue for further 5 months as an alternative to the patient attending for further clinic appointments for administration of triptorelin. Previously at ENHT, triptorelin was the only gonadorelin analogue on formulary for gynaecological indications. At WHHT buserelin nasal spray 150mcg/dose is RED (hospital only) for infertility & endometriosis indications. Nafarelin nasal spray 2mg/ml is licensed for: . The hormonal management of endometriosis, including pain relief and reduction of endometriotic lesions. Use in controlled ovarian stimulation programmes prior to in-vitro fertilisation, under the supervision of an infertility specialist. Use of nafarelin in endometriosis aims to induce chronic pituitary desensitisation, which gives a menopause-like state maintained over many months.
    [Show full text]
  • Contraception and Misconceptions
    CONTRACEPTION AND MISCONCEPTIONS CONTRACEPTION IN WOMEN WITH MENTAL ILLNESS OVERVIEW Hormones and mood How mental illness impacts on contraceptive choice Ideal contraception Pro and cons of contraceptive methods in women with mental illness Hormonal contraception and mood ESTROGENS anti-inflammatory neuroprotective effects of estradiol modulation of the limbic processing memory of emotionally-relevant information. estradiol “beneficially” modulates pathways implicated in the pathophysiology of depression, including serotonin and norepinephrine pathways PROGESTROGENS Previously thought to be anxiogenic, depressogenic Breakdown products Depression – alpha hydroxy progestrogen breakdown products pro – inflammatory, anxiogenic HORMONES AND MOODS – COMPLEX INTERPLAY MENTAL ILLNESS AND CONTRACEPTIVE CHOICE Effect of mental illness on contraceptive choice Effect of contraceptive choice on mental illness Drug interactions EFFECT MENTAL ILLNESS ON CONTRACEPTIVE CHOICE Impulsive Poor planning Cognitive and problem judgement Poor adherence IMPULSIVITY COGNITION POOR JUDGEMENT LETS NOT FORGET SUBSTANCES…… TYPES OF CONTRACEPTION No method Non hormonal Condom/Femidom Diaphragm Non hormone containing IUCD (Copper T) Hormonal COC POP Mirena Evra Patch Nuva Ring Implant ORAL CONTRACEPTIVES POP – avoid Same time every day COC Pros Effective Reduction PMS – monophasic estrogen dominant pill eg Femodene, Yaz, Nordette Cons Drug interactions Pill burden Daily dose EVRA PATCH Weekly patch Transdermal system: 150 mcg/day
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Nafarelin Acetate (Synarel) Reference Number: PA.CP.PHAR.174 Effective Date: 01/18 Coding Implications Last Review Date: 10/18 Revision Log
    Clinical Policy: Nafarelin Acetate (Synarel) Reference Number: PA.CP.PHAR.174 Effective Date: 01/18 Coding Implications Last Review Date: 10/18 Revision Log Description The intent of the criteria is to ensure that patients follow selection elements established by Pennsylvania Health and Wellness® medical policy for the use of nafarelin acetate (Synarel®). FDA Approved Indication(s) Synarel is indicated for: • Treatment of CPP (gonadotropin-dependent precocious puberty) in children of both sexes; • Management of endometriosis, including pain relief and reduction of endometriotic lesions. Policy/Criteria It is the policy of Pennsylvania Health and Wellness that Synarel is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Central Precocious Puberty (must meet all): 1. Diagnosis of central precocious puberty confirmed by all of the following (a through c): a. Elevated basal luteinizing hormone (LH) level > 0.2 - 0.3 mIU/L (dependent on type of assay used) and/or elevated leuprolide-stimulated LH level > 3.3 - 5 IU/I (dependent on type of assay used); b. Difference between bone age and chronological age was > 1 year (bone age- chronological age; c. Age at onset of secondary sex characteristics is < 8 years if female, or < 9 years if male; 2. Member meets the following age requirements: a. Female: 2 - 11 years; b. Male: 2 - 12 years; 3. Prescribed by or in consultation with a pediatric endocrinologist; 4. Dose does not exceed 1800 micrograms per day. Approval duration: 12 months B. Endometriosis (must meet all): 1. Diagnosis of endometriosis; 2. Prescribed by or in consultation with a gynecologist; 3.
    [Show full text]
  • 209627Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209627Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review Reviewers of Multi-Disciplinary Review and Evaluation SECTIONS OFFICE/ AUTHORED/ ACKNOWLEDGED/ DISCIPLINE REVIEWER DIVISION APPROVED Mark Seggel, Ph.D. OPQ/ONDP/DNDP2 Authored: Section 4.2 Digitally signed by Mark R. Seggel -S CMC Lead DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Mark R. Signature: Mark R. Seggel -S Seggel -S, 0.9.2342.19200300.100.1.1=1300071539 Date: 2018.08.08 16:29:15 -04'00' Frederic Moulin, DVM, PhD OND/ODE3/DBRUP Authored: Section 5 Pharmacology/ Digitally signed by Frederic Moulin -S Toxicology DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Reviewer Signature: Frederic Moulin -S 0.9.2342.19200300.100.1.1=2001708658, cn=Frederic Moulin -S Date: 2018.08.08 15:26:57 -04'00' Kimberly Hatfield, PhD OND/ODE3/DBRUP Approved: Section 5 Pharmacology/ Toxicology Digitally signed by Kimberly P. Hatfield -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Team Leader Signature: Kimberly P. Hatfield -S 0.9.2342.19200300.100.1.1=1300387215, cn=Kimberly P. Hatfield -S Date: 2018.08.08 14:56:10 -04'00' Li Li, Ph.D. OCP/DCP3 Authored: Sections 6 and 17.3 Clinical Pharmacology Dig ta ly signed by Li Li S DN c=US o=U S Government ou=HHS ou=FDA ou=People Reviewer cn=Li Li S Signature: Li Li -S 0 9 2342 19200300 100 1 1=20005 08577 Date 2018 08 08 15 39 23 04'00' Doanh Tran, Ph.D.
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]
  • Research Publications by DISTINCTIONS Any Scientist of Pakistan in Last 10 Year and SERVICES  Secretary General, the Chemical Society of Pakistan
    CV and List of Publications PROF. DR. MUHAMMAD IQBAL CHOUDHARY (Hilal-e-Imtiaz, Sitara-e-Imtiaz, Tamgha-ei-Imtiaz) International Center for Chemical and Biological Sciences (H. E. J. Research Institute of Chemistry, Dr. Panjwani Center for Molecular Medicine and Drug Research) University of Karachi, Karachi-75270 Pakistan Tel: (92-21) 34824924, 34824925 Fax: 34819018, 34819019 E-mail: [email protected] Web Page: www.iccs.edu Biodata and List of Publications Pag No. 2 MUHAMMAD IQBAL CHOUDHARY (Hilal-e-Imtiaz, Sitara-e-Imtiaz, Tamgha-e-Imtiaz) D-131, Phase II, D. O. H. S., Malir Cant., Karachi-75270, Pakistan Ph.: 92-21-4901110 MAILING INTERNATIONAL CENTER FOR CHEMICAL AND BIOLOGICAL SCIENCES ADDRESS (H. E. J. Research Institute of Chemistry Dr. Panjwani Center for Molecular Medicine and Drug Research) University of Karachi Karachi-74270, Pakistan Tel: (92-21) 34824924-5 Fax: (92-21) 34819018-9 Email: [email protected] Web: www.iccs.edu DATE OF BIRTH September 11, 1959 (Karachi, Pakistan) EDUCATION Doctor of Science (D.Sc.) (University of Karachi ) 2005 Ph.D. (Organic Chemistry) 1987 H. E. J. Research Institute of Chemistry University of Karachi, Karachi-75270, Pakistan Thesis Title: "The Isolation and Structural Studies on Some Medicinal Plants of Pakistan, Buxus papillosa, Catharanthus roseus, and Cissampelos pareira." M.Sc. (Organic Chemistry) 1983 University of Karachi, Karachi-75270, Pakistan B.Sc. (Chemistry, Biochemistry, Botany) 1980 University of Karachi, Karachi-75270, Pakistan AWARDS & Declared as the top most scientist (Number 1) among 1,650 HONORS scientists of Pakistan in all disciplines / fields of science and technology (year 2012) by the Pakistan Council for Science and Technology (Ministry of Science and Technology), Pakistan.
    [Show full text]